Table 1 

Vaginal application of FSL1 significantly delayed HSV2 disease development and increased survival times. 

FSL1 and vehicle groups^{a} 
Time to symptoms^{b} 
Survival time^{c} 
Survival^{d} 
(days) 
(days) 
(%) 



FSL1 2 μg 24 h prior 
8.0 (6.49.7)^{e, f} 
9.4 (7.811.0)^{e, f} 
1/10 (10) 
FSL1 2 μg 6 h prior 
9.0 (8.19.9)^{e, f} 
10.1 (8.911.3)^{e, f} 
0/10 (0) 
FSL1 2 μg 1 h prior, 1 h after 
6.0 (5.56.4) 
7.3 (6.87.7) 
0/10 (0) 
FSL1 2 μg 6 h, 5 h, 4 h prior 
6.4 (5.97.0) 
9.1 (7.011.2) 
1/9 (11) 
FSL1 6 μg 6 h prior 
8.5 (6.79.9)^{e, f} 
10.0 (8.411.6)^{e, f} 
4/10 (40) 
DPBS vehicle control 
5.8 (5.06.4) 
7.2 (6.97.6) 
0/8 (0) 


^{a }Intravaginal application of FSL1 or DPBS vehicle control at selected times prior to or after vaginal inoculation of HSV2 (10^{4}pfu). ^{b }Mean (95% confidence interval) for day that each mice first showed disease signs within 14d PI ^{c }Mean (95% confidence interval) for day that each mice succumbed to disease within 14d PI. ^{d }Number of mice that did not succumb to disease within 14d PI/total number of animals in the group (percent survival). ^{e }p < 0.05 compared to DPBS vehicle control (ANOVA, Dunnett's Test). ^{f }p < 0.05 compared to FSL1 2 μg 1 h prior, 1 h after (ANOVA, Dunnett's Test). 

Rose et al. Virology Journal 2009 6:195 doi:10.1186/1743422X6195 